Regulation & law · 06/10/2021

National Cancer Institute to Grant Exclusive Patent License to Ares Immunotherapy for T Cell Therapies

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Ares Immunotherapy, a Delaware-based biotech company, to develop and commercialize T cell therapies for cancers that express the mesothelin protein.